Gaithersburg, MD - June 22, 2023 Cartesian Therapeutics, a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper ...
Multiple system atrophy (MSA) is an adult-onset, rapidly progressive neurodegenerative disorder characterised by the aggregation of α-synuclein in oligodendroglial cytoplasmatic inclusions.1 ...
In the current edition of The Lancet Neurology, researchers of the Human Brain Project (HBP) present the novel clinical uses of advanced brain modelling methods. Computational brain modelling ...
There are 3.4 billion individuals living with a neurological condition, making disorders affecting the nervous system the leading cause of illness and disability globally, according to a new study in ...
The first FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab demonstrated a sustained reduction in ...
TOKYO, Nov. 15, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that The Lancet Neurology published a preliminary data analysis from ...
High blood pressure is the main modifiable risk factor for preventing cardiovascular events in people who have had a stroke or transient ischaemic attack; however, only approximately one in three ...
The Calgary Stroke Program, a joint University of Calgary and Alberta Health Services initiative at Foothills Medical Centre, has been involved with three papers published this week in The Lancet and ...
Gaps in the U.S. stroke transfer system are drastically reducing survivors' chances of receiving critical treatment and increasing the likelihood that they will leave the hospital with a disability, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results